Evidence map›Paper›PMID 29062228›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2017

Impact and prevention of severe exacerbations of COPD: a review of the evidence.

David Mg Halpin, Marc Miravitlles, Norbert Metzdorf, Bartolomé Celli

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 150 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 11 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06865703 nacompletednot on this mapstarted 2025, after this paper: background citation

Efficacy of Different Osteopathic Manipulative Techniques Combined With Diaphragmatic Release in Patients With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorBeni-Suef UniversityRan2025 to 2025Enrolled66ConditionsCopdArmsdiaphragmatic release technique, rib raising technique in group A, THORACIC LYMPHATIC PUMP TECHNIGUE
NCT07749001 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Airway Dysfunction, Occlusions and RemodEling: COPD Patients and Mepolizumab (ADORE)

TypeinterventionalSponsorWestern University, CanadaRan2026 to 2028Enrolled36ConditionsCOPD (Chronic Obstructive Pulmonary Disease)ArmsMepolizumab 100 MG Injection
3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 11 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Predictors of Acute Exacerbations in COPD: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

David Mg HalpinDepartment of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK.
Marc MiravitllesPneumology Department, Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
Norbert MetzdorfRespiratory Medicine, Boehringer Ingelheim Pharma GmBH & Co KG, Ingelheim am Rhein, Germany.
Bartolomé CelliPulmonary Division, Brigham and Women's Hospital, Boston, MA, USA.
Boehringer Ingelheim (Germany) · DEBrigham and Women's Hospital · USCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESRoyal Devon and Exeter Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical implications for patients and significant economic consequences for society. The prevalence and burden of severe COPD exacerbations remain high, despite recognition of the importance of exacerbation prevention and the availability of new treatment options. Severe COPD exacerbations are associated with high mortality, have negative impact on quality of life, are linked to cardiovascular complications, and are a significant burden on the health-care system. This review identified risk factors that contribute to the development of severe exacerbations, treatment options (bronchodilators, antibiotics, corticosteroids [CSs], oxygen therapy, and ventilator support) to manage severe exacerbations, and strategies to prevent readmission to hospital. Risk factors that are amenable to change have been highlighted. A number of bronchodilators have demonstrated successful reduction in risk of severe exacerbations, including long-acting muscarinic antagonist or long-acting β

Indexed as

Adrenal Cortex HormonesAnti-Bacterial AgentsBronchodilator AgentsDisease ProgressionEvidence-Based MedicineHospital MortalityHumansLungOxygen Inhalation TherapyPulmonary Disease, Chronic ObstructiveQuality of LifeRecovery of FunctionRespiration, ArtificialRespiratory TherapyRisk FactorsRisk Reduction BehaviorAdrenal Cortex HormonesAnti-Bacterial AgentsBronchodilator Agentsbronchodilatorshospitalizationlong-acting muscarinic antagonistpreventionsevere COPD exacerbationstreatment

Identifiers

PMID29062228
PMCPMC5638577
OpenAlexW2761298511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.